Dr Sarah Elizabeth Norris, DO | |
601 W 2nd St, Bloomington, IN 47403-2317 | |
(181) 235-3951 | |
Not Available |
Full Name | Dr Sarah Elizabeth Norris |
---|---|
Gender | Female |
Speciality | Emergency Medicine |
Experience | 10 Years |
Location | 601 W 2nd St, Bloomington, Indiana |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1932692431 | NPI | - | NPPES |
Facility Name | Location | Facility Type |
---|---|---|
Henry County Memorial Hospital | New castle, IN | Hospital |
Ascension St Vincent Hospital | Indianapolis, IN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Cep America Llc | 6608056171 | 575 |
News Archive
Aptuit, Inc. today announced the publication of new research in the December issue of the European Journal of Pharmaceutical Sciences, the official journal of the European Federation for Pharmaceutical Sciences (EUFEPS), which describes the solid-state characterization of three forms of finasteride.
PAREXEL International, a leading global biopharmaceutical services organization, today announced the launch of its Perceptive MyTrials® Data-Driven Monitoring solution.
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Kansas State University is helping the fight against Zika virus through mosquito research.
› Verified 5 days ago
Entity Name | Indiana University Health Southern Indiana Physicians Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1013953983 PECOS PAC ID: 6204748197 Enrollment ID: O20040423000556 |
News Archive
Aptuit, Inc. today announced the publication of new research in the December issue of the European Journal of Pharmaceutical Sciences, the official journal of the European Federation for Pharmaceutical Sciences (EUFEPS), which describes the solid-state characterization of three forms of finasteride.
PAREXEL International, a leading global biopharmaceutical services organization, today announced the launch of its Perceptive MyTrials® Data-Driven Monitoring solution.
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Kansas State University is helping the fight against Zika virus through mosquito research.
› Verified 5 days ago
Entity Name | Cep America Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1285103671 PECOS PAC ID: 6608056171 Enrollment ID: O20190214000611 |
News Archive
Aptuit, Inc. today announced the publication of new research in the December issue of the European Journal of Pharmaceutical Sciences, the official journal of the European Federation for Pharmaceutical Sciences (EUFEPS), which describes the solid-state characterization of three forms of finasteride.
PAREXEL International, a leading global biopharmaceutical services organization, today announced the launch of its Perceptive MyTrials® Data-Driven Monitoring solution.
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Kansas State University is helping the fight against Zika virus through mosquito research.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Sarah Elizabeth Norris, DO 250 N Shadeland Ave, Indianapolis, IN 46219-4959 Ph: () - | Dr Sarah Elizabeth Norris, DO 601 W 2nd St, Bloomington, IN 47403-2317 Ph: (181) 235-3951 |
News Archive
Aptuit, Inc. today announced the publication of new research in the December issue of the European Journal of Pharmaceutical Sciences, the official journal of the European Federation for Pharmaceutical Sciences (EUFEPS), which describes the solid-state characterization of three forms of finasteride.
PAREXEL International, a leading global biopharmaceutical services organization, today announced the launch of its Perceptive MyTrials® Data-Driven Monitoring solution.
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Kansas State University is helping the fight against Zika virus through mosquito research.
› Verified 5 days ago
Ronald C Jenson, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4794 Red Oak Ln, Bloomington, IN 47401 Phone: 812-396-9620 | |
Dr. Robert Stone, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 514 W 2nd St, Bloomington, IN 47403 Phone: 812-353-3719 Fax: 812-353-3713 | |
Dr. Christina M Cabott, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 601 W 2nd St, Bloomington, IN 47403 Phone: 812-336-1690 Fax: 812-349-1325 | |
Dr. John Austin Lee, MD, MPH Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2651 E Discovery Pkwy, Bloomington, IN 47408 Phone: 812-353-9515 Fax: 812-353-9275 | |
Dr. Carlyle George Langhorn Jr., M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2651 E Discovery Pkwy, Bloomington, IN 47408 Phone: 812-353-9515 | |
Jonathan D Hart, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2605 E Creeks Edge Dr, Bloomington, IN 47401 Phone: 812-355-2300 Fax: 812-355-2316 | |
Mary Smith, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 601 W 2nd St, Bloomington, IN 47403 Phone: 812-353-9515 Fax: 812-353-9275 |